Ixekizumab Associated New-Onset Inflammatory Bowel Disease

Ixekizumab is a monoclonal antibody targeting interleukin-17 approved for the treatment of psoriasis. In a recent post hoc meta-analysis of Phase-I to Phase-III clinical trials of anti-interleukin-17 agents for the treatment of plaque psoriasis, there was a rare association (<1%) with induction o...

Descripción completa

Detalles Bibliográficos
Autores principales: Nazarian, Amir, Grin, Andrea, Wijeratne, Don Thiwanka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209798/
https://www.ncbi.nlm.nih.gov/pubmed/32440523
http://dx.doi.org/10.14309/crj.0000000000000316
Descripción
Sumario:Ixekizumab is a monoclonal antibody targeting interleukin-17 approved for the treatment of psoriasis. In a recent post hoc meta-analysis of Phase-I to Phase-III clinical trials of anti-interleukin-17 agents for the treatment of plaque psoriasis, there was a rare association (<1%) with induction or exacerbation of inflammatory bowel disease. We report a case of new-onset ileal Crohn's disease in a 48-year-old woman on ixekizumab for psoriasis.

Ejemplares similares